Additionally, understanding the biological mechanism behind CYP4Z1 activation could help in the design of prodrugs that are selectively activated in breast tumor tissue, minimizing systemic side effects of chemotherapy. The gene discussed is CYP4Z1; the disease is breast neoplasm.